Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.

<h4>Introduction</h4>Changes in the pulmonary surfactant have been seen in severe COVID-19, but data on mild to moderate COVID-19 is scarce. The aim of this study was to explore the protein and phospholipid profiles in the small airways in patients with mild to moderate COVID-19.<h4&g...

Full description

Saved in:
Bibliographic Details
Main Authors: Spela Kokelj, Per Larsson, Emilia Viklund, Hatice Koca, Hanna Slogén, Lowie Vanfleteren, Bo Nilsson, Karin Fromell, Johan Westin, Anna-Carin Olin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0325153
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849228185181356032
author Spela Kokelj
Per Larsson
Emilia Viklund
Hatice Koca
Hanna Slogén
Lowie Vanfleteren
Bo Nilsson
Karin Fromell
Johan Westin
Anna-Carin Olin
author_facet Spela Kokelj
Per Larsson
Emilia Viklund
Hatice Koca
Hanna Slogén
Lowie Vanfleteren
Bo Nilsson
Karin Fromell
Johan Westin
Anna-Carin Olin
author_sort Spela Kokelj
collection DOAJ
description <h4>Introduction</h4>Changes in the pulmonary surfactant have been seen in severe COVID-19, but data on mild to moderate COVID-19 is scarce. The aim of this study was to explore the protein and phospholipid profiles in the small airways in patients with mild to moderate COVID-19.<h4>Methods</h4>29 cases with COVID-19 and 17 healthy controls were examined at baseline. 22 cases were re-examined at follow-up after recovery from COVID-19. Airwave oscillometry was performed and the biological material from the respiratory tract lining fluid was collected with the PExA (Particles in Exhaled Air) method. SOMAscan was used for the analysis of proteins, and liquid chromatography with tandem mass spectrometry (LC-MS/MS) for phospholipids.<h4>Results</h4>95 lipid species belonging to 8 lipid classes, and 46 proteins were analysed. Relative amounts of 13 lipid species differed between cases and controls at baseline, and of 24 lipid species at follow-up. At follow-up, the phosphatidylethanolamine class (PE) was significantly lower in cases at than in controls, and a significant decrease in PE, as well as a change in 20 lipid species from baseline to follow-up in cases was seen. The protein profile did not differ between cases and controls either at baseline or follow-up, or between repeated measurements in cases.<h4>Conclusions</h4>The observed alterations in the surfactant phospholipids in the RTLF indicate that surfactant homeostasis is affected already in mild to moderate COVID-19, and these changes appear to persist over time.
format Article
id doaj-art-d52210e2c7464b9395472473ae1aedbc
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-d52210e2c7464b9395472473ae1aedbc2025-08-23T05:32:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01208e032515310.1371/journal.pone.0325153Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.Spela KokeljPer LarssonEmilia ViklundHatice KocaHanna SlogénLowie VanfleterenBo NilssonKarin FromellJohan WestinAnna-Carin Olin<h4>Introduction</h4>Changes in the pulmonary surfactant have been seen in severe COVID-19, but data on mild to moderate COVID-19 is scarce. The aim of this study was to explore the protein and phospholipid profiles in the small airways in patients with mild to moderate COVID-19.<h4>Methods</h4>29 cases with COVID-19 and 17 healthy controls were examined at baseline. 22 cases were re-examined at follow-up after recovery from COVID-19. Airwave oscillometry was performed and the biological material from the respiratory tract lining fluid was collected with the PExA (Particles in Exhaled Air) method. SOMAscan was used for the analysis of proteins, and liquid chromatography with tandem mass spectrometry (LC-MS/MS) for phospholipids.<h4>Results</h4>95 lipid species belonging to 8 lipid classes, and 46 proteins were analysed. Relative amounts of 13 lipid species differed between cases and controls at baseline, and of 24 lipid species at follow-up. At follow-up, the phosphatidylethanolamine class (PE) was significantly lower in cases at than in controls, and a significant decrease in PE, as well as a change in 20 lipid species from baseline to follow-up in cases was seen. The protein profile did not differ between cases and controls either at baseline or follow-up, or between repeated measurements in cases.<h4>Conclusions</h4>The observed alterations in the surfactant phospholipids in the RTLF indicate that surfactant homeostasis is affected already in mild to moderate COVID-19, and these changes appear to persist over time.https://doi.org/10.1371/journal.pone.0325153
spellingShingle Spela Kokelj
Per Larsson
Emilia Viklund
Hatice Koca
Hanna Slogén
Lowie Vanfleteren
Bo Nilsson
Karin Fromell
Johan Westin
Anna-Carin Olin
Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
PLoS ONE
title Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
title_full Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
title_fullStr Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
title_full_unstemmed Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
title_short Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
title_sort changes in the pulmonary surfactant in patients with mild to moderate covid 19
url https://doi.org/10.1371/journal.pone.0325153
work_keys_str_mv AT spelakokelj changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT perlarsson changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT emiliaviklund changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT haticekoca changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT hannaslogen changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT lowievanfleteren changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT bonilsson changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT karinfromell changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT johanwestin changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19
AT annacarinolin changesinthepulmonarysurfactantinpatientswithmildtomoderatecovid19